jueves, 21 de enero de 2016

Síndrome de Brugada / Brugada syndrome

Enero 21, 2016. No. 2213


 



 Síndrome de Brugada; Aspectos clínicos, genéticos, moleculares, celulares e iónicos
Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects.
Curr Probl Cardiol. 2016 Jan;41(1):7-57. doi: 10.1016/j.cpcardiol.2015.06.002. Epub 2015 Jun 11.
Abstract
Brugada syndrome (BrS) is an inherited cardiac arrhythmia syndrome first described as a new clinical entity in 1992. Electrocardiographically characterized by distinct coved type ST segment elevation in the right-precordial leads, the syndrome is associated with a high risk for sudden cardiac death in young adults, and less frequently in infants and children. The electrocardiographic manifestations of BrS are often concealed and may be unmasked or aggravated by sodium channel blockers, a febrile state, vagotonic agents, as well as by tricyclic and tetracyclic antidepressants. An implantable cardioverter defibrillator is the most widely accepted approach to therapy. Pharmacologic therapy is designed to produce an inward shift in the balance of currents active during the early phases of the right ventricular action potential (AP) and can be used to abort electrical storms or as an adjunct or alternative to device therapy when use of an implantable cardioverter defibrillator is not possible. Isoproterenol, cilostazol, and milrinone boost calcium channel current and drugs like quinidine, bepridil, and the Chinese herb extract Wenxin Keli inhibit the transient outward current, acting to diminish the AP notch and thus to suppress the substrate and trigger for ventricular tachycardia or fibrillation. Radiofrequency ablation of the right ventricular outflow tract epicardium of patients with BrS has recently been shown to reduce arrhythmia vulnerability and the electrocardiographic manifestation of the disease, presumably by destroying the cells with more prominent AP notch. Thisreview provides an overview of the clinical, genetic, molecular, and cellular aspects of BrS as well as the approach to therapy.
 Síndrome de Brugada
Begoña Benito, Josep Brugada, Ramón Brugada y Pedro Brugada
Rev Esp Cardiol. 2009;62(11):1297-315
 Síndrome de Brugada y su relevancia en el periodo perioperatorio
Brugada syndrome and its relevance in the perioperative period.
Ann Card Anaesth. 2015 Jul-Sep;18(3):403-13. doi: 10.4103/0971-9784.159812.
Abstract
Brugada syndrome is an autosomal dominant genetic disorder associated with an increased risk of sudden cardiac death, as well as ventricular tachyarrhythmias.The defective cardiac sodium channels result in usual electrocardiographic findings of a coved-type ST elevation in precordial leads V1 to V3. The majority of patients have uncomplicated courses with anesthesia, surgery, and invasive procedures. However there is risk of worsening ST elevation and ventricular arrhythmias due to perioperative medications, surgical insult, electrolyte abnormalities, fever, autonomic nervous system tone, as well as other perturbations. Given the increasing numbers of patients with inherited conduction disorders presenting for non-cardiac surgery that are at risk of sudden cardiac death, safe anesthetic management depends upon a detailed knowledge of these conditions.
JACCOA


          
Anestesiología y Medicina del Dolor

52 664 6848905

Copyright © 2015
Publicar un comentario en la entrada